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Abstract
Pituitary tumors are not rare if prevalence rates from autopsy or radiological series are considered; approximately 0.5% of all
pituitary adenomas will come to medical attention. Less than 0.1% of these pituitary adenomas will become malignant, and
probably around 0.5% of all detected adenomas will display an aggressive course. However, the exact incidence of both
aggressive pituitary adenomas and pituitary carcinomas is unknown, as most data come from series with selected patients, such
as surgically treated patients, which is likely not a reflection of all patients with a pituitary adenoma. An aggressive pituitary
adenoma is not well-defined; even though an overarching definition, capturing both immunohistochemical and clinical charac-
teristics is probably not waterproof, adoption of a widely accepted definition will be very helpful to harmonize research and
establish more reliable epidemiological data.
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Detailed knowledge on the epidemiology of a condition based
on scientific literature, i.e. knowledge regarding its occurrence
and prevalence, assumes a definition of the condition under
study. Unfortunately, such common definition is lacking for
aggressive pituitary tumors [1, 2], which hampers the clear
epidemiological picture. The case is somewhat clearer for pi-
tuitary carcinomas, which are defined as pituitary tumors that
exhibit metastasis [3].
Pituitary tumors are not rare if prevalence rates from autop-
sy or radiological series are considered: a meta-analysis from
pooled autopsy and radiological series showed average prev-
alence rates of 14.4% (range 1–35%) and 22.5% (range 1–
40%), respectively [4]. Most pituitary tumors thus go unno-
ticed during life.
The incidence of clinically apparent pituitary adenomas
(quantifying the number of new cases), depends on sex and
age. Based on data from registers with national coverage,
prolactinomas are found most frequently, with an estimated
incidence rate of 10/100,000 person-years in women of repro-
ductive age [5]. The incidence for other adenomas is lower [5],
being around 1–4/100,000 person-years for nonfunctioning
adenomas, 0.4/100,000 person-years for GH secreting adeno-
mas and 0.2/100,000 person-years for ACTH secreting ade-
nomas. The prevalence of clinically significant adenomas that
present to medical attention, as determined in cross-sectional
community-based studies in Belgium and the UK ranged from
78 to 94 cases per 100,000 inhabitants [6, 7]. Combining these
data with those from autopsy series as described above, sug-
gests that approximately 0.5% of all pituitary tumors will
come to medical attention, underlining the apparent very in-
dolent nature of pituitary adenomas (see Fig. 1).
Depending on size, all pituitary adenomas can show growth
potential; in series with conservatively managed nonfunctioning
adenomas (i.e. under monitoring surveillance), 10% of
microadenomas and 23% of macroadenomas display growth
[8]. Also, a decrease in tumor size is described [8, 9], confirming
that there is no invariable growth pattern in these tumors.
Generally, there are two approaches when characterizing an
aggressive pituitary tumor: a histopathological and a clinical
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one. For the histopathological approach, markers of prolifer-
ation, such as a high Ki-67 index, increased mitoses, or exten-
sive p53 staining are considered hallmarks of a more aggres-
sive behavior. This was reflected in the 2004 WHO classifi-
cation of pituitary adenomas, with Ki-67 labeling index >3%,
and extensive p-53 staining as classification criteria for so
called atypical adenomas [1]. This combination of prolifera-
tion markers is found in 3–15% of all pituitary adenomas [10,
11]. The WHO 2004 classification was in line with observa-
tions that the vast majority of pituitary adenomas have Ki-67
indexes <3%, whereas >10% is mainly seen in pituitary tu-
mors with a more aggressive behavior [12]. Similarly, high
p53 expression is more often found in aggressive pituitary
tumors [12].
The new WHO 2017 classification does not refer to atyp-
ical adenomas as distinct entity and only distinguishes pitui-
tary carcinomas [3]. The main reason is twofold. Low Ki-67
and negative p53 staining is found in approximately 20% of
true aggressive pituitary tumors and pituitary carcinomas [13],
showing that these markers, although related to risk of recur-
rence [14] will not perfectly predict aggressive adenoma be-
havior. Also there is no agreement on the set of markers and
cut-offs to be used [1]. The 2004 WHO classification of atyp-
ical pituitary adenomas was therefore not considered suffi-
cient to guide management of pituitary adenomas.
However, not only markers of proliferation are still consid-
ered relevant for aggressive behavior [3], also local factors
like cavernous sinus and/or sphenoid sinus invasion and tu-
mor microenvironment, are considered relevant. Secretion of
chemokines by the tumor facilitate macrophage, neutrophil,
and T cell recruitment into the tumor [15], and tumor
associated fibroblasts cultured from clinically non-
functioning adenomas and somatotropinomas, secreted more
IL-6 in those cases that presented with cavernous sinus inva-
sion compared to fibroblasts from non-invasive tumors [16].
A second approach considers an invasive tumor with ab-
normal growth pattern and multiple recurrences despite
multimodality treatment including surgery, radiotherapy, and
medical treatment as indicative for an aggressive pituitary ad-
enoma [2]. Such clinical characterization of aggressiveness
leaves room for different interpretations as many aspects are
undefined. How many recurrences, over what time period and
following what kind of treatments? We likely see an acromeg-
aly patient with a third recurrence in 25 years despite surgery,
radiotherapy and medical treatment different from a patient
with a fourth biochemical recurrence in two years with clear
signs of further growth of the large tumor. This lack of clarity
with regard to the definition will thus hamper an accurate
estimation of the incidence of aggressive pituitary adenomas.
Mind that this definition explicitly takes the invasiveness, as
well as the unusual growth pattern into account, meaning that
an adenoma that is difficult to treat only from a biochemical
perspective is not considered an aggressive pituitary adenoma.
Also, it is not only the size of the tumor that determines its
aggressiveness, and in giant prolactinomas (tumor diameter >
4 cm) excellent responses to medical therapy are well-known
[17]. In a large series of aggressive pituitary adenomas, the
majority was clinically functioning [13].
The definition of an aggressive adenoma includes invasive-
ness; in a large series of nonfunctioning pituitary
macroadenomas treated surgically, 94% of patients had resid-
ual tumor visible on postoperative imaging [18]; in a
Fig. 1 Estimated incidence for aggressive pituitary adenomas
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pathological series of patients with functioning and nonfunc-
tioning adenomas, microscopic evidence of dural invasion
was found in 88% of macroadenomas and 94% of adenomas
with extrasellar extension [19]. Mind that these numbers can-
not be translated to all pituitary adenomas, even not
macroadenomas, as these series are based on surgically treated
adenomas, i.e. a selection of all (macro)adenomas with a
higher likelihood of invasiveness.
If we consider regrowth after treatment as the first hallmark
of aggressiveness, several studies show that approximately
20–50% of patients with a nonfunctioning adenoma display
signs of regrowth five years after initial surgery [9, 20]; this
number is lower if additional radiotherapy is applied [20].
After ten years, the percentage of patients with a regrowth of
the adenoma is >50% [20]. In series on hormone secreting
adenomas, the recurrence risk is lower after medical treatment
or surgery, but it needs to be acknowledged that in
prolactinomas [21], acromegaly [22] and Cushing’s disease
[23–25] the tumor size at detection and treatment is smaller
compared to nonfunctioning adenomas.
In large a series of 765 patients with a nonfunctioning pi-
tuitary adenoma, 90 had a second tumor regrowth; the esti-
mated 5-year probability of second regrowth was 35% after a
first regrowth [18]. In the same study, the 5-year probability of
a third regrowth was 26%. Importantly, these numbers were
dependent on type of treatment, with the lowest regrowth
probability after treatment with radiotherapy and/or surgery.
For example, the risk for a second regrowth was 13% after
combined surgery and radiotherapy, and 63% in patients with
an expectant approach. These data suggest that 2–3% of pa-
tients with a macroadenoma display a regrowth a least 3 times.
Two important lessons can thus be learned from this study.
Firstly, a number of patients harboring a pituitary adenoma
show multiple recurrences over time; secondly, this risk is
related to treatment modalities. Still, this 2–3% does not rep-
resent the percentage of patients with an aggressive adenoma
according to the definition outlined above, as many of these
patients did not have multiple lines of treatment. We could,
however, argue that ~2% reflects the upper limit of the per-
centage of patients with a pituitary macroadenoma that can be
classified as an aggressive adenoma.
In a large database, containing tissues from 3489 pituitary
adenomas, 5 (0.12%) were classified as pituitary carcinoma
[26]. Mind however that this is not a reflection of the malig-
nancy risk in all pituitary adenomas as this series is a selection,
i.e. adenomas for which surgical treatment was considered
appropriate. In the largest series published on aggressive pitu-
itary adenomas and pituitary carcinomas, 40 carcinomas and
116 aggressive adenomas were included [13]. Although the
sampling frame of the study was not well-defined, it suggests
that an aggressive adenoma is 3–4 times more common than a
pituitary carcinoma. This would translate in an estimated per-
centage of 0.3–0.5% of all macroadenomas being aggressive.
There is currently a debate whether aggressive pituitary
adenomas and carcinomas are categories that need to be sep-
arated [27]. And the more general question is whether indolent
adenomas that escape detection, pituitary adenomas with a
course that comes to clinical attention, and aggressive pitui-
tary adenomas/carcinomas comprise fully distinct entities.
Currently, there are no convincing arguments that these are
biologically and clinically distinct entities; more likely the
categories overlap and adenomas can even change their be-
havior during life [28, 29]. This is depicted in Fig. 1.
To conclude, less than 0.1% of all detected pituitary ade-
nomas will becomemalignant, and probably around 0.5%will
display an aggressive course. If we consider all adenomas
(also the small adenomas with an indolent course), the per-
centage aggressive pituitary adenomas/carcinomas is much
lower (see Fig. 1). However, the exact incidence of both ag-
gressive pituitary adenomas and pituitary carcinomas is un-
known. This is related to two factors:
Most data come from series with selected patients, such as
surgically treated patients, which is likely not a reflection of all
patients with a pituitary adenoma. The reported and estimated
incidence of aggressive behavior (~0.5%) and pituitary carci-
noma (~0.1) is thus a likely overestimation of the true risk.
An aggressive pituitary adenoma is not well-defined; even
though an overarching definition, capturing both immunohis-
tochemical and clinical characteristics is probably not water-
proof, adoption of a widely accepted definition will be very
helpful to harmonize research and establish more reliable ep-
idemiological data.
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